Log In
Print
BCIQ
Print
Print this Print this
 

Huntexil, pridopidine (formerly ACR16)

  Manage Alerts
Collapse Summary General Information
Company Teva Pharmaceutical Industries Ltd.
DescriptionDopamine stabilizer
Molecular Target Dopamine receptor
Mechanism of ActionDopamine stabilizer
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationHuntington's disease (HD)
Indication DetailsTreat Huntington's disease (HD); Treat symptoms of Huntington's disease (HD)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

$26.1M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today